Health Care & Life Sciences » Pharmaceuticals | Synergy Pharmaceuticals Inc.

Synergy Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Sales/Revenue
-
-
-
-
16,820.00
Cost of Goods Sold (COGS) incl. D&A
56.00
120.00
163.00
233.00
8,811.00
Gross Income
56.00
120.00
163.00
233.00
8,009.00
SG&A Expense
62,255.00
94,158.00
99,659.00
145,053.00
230,208.00
EBIT
62,311.00
94,278.00
99,822.00
145,286.00
222,199.00
Unusual Expense
149.00
1,362.00
394.00
40,052.00
3,131.00
Interest Expense
21.00
2,875.00
17,284.00
13,390.00
5,270.00
Pretax Income
62,124.00
95,791.00
117,500.00
198,728.00
224,338.00
Income Tax
-
83.00
-
121.00
-
Consolidated Net Income
62,124.00
95,708.00
117,500.00
198,607.00
224,338.00
Net Income
62,124.00
95,708.00
117,500.00
198,607.00
224,338.00
Net Income After Extraordinaries
62,124.00
95,708.00
117,500.00
198,607.00
224,338.00
Net Income Available to Common
62,124.00
95,708.00
117,500.00
198,607.00
224,338.00
EPS (Basic)
0.73
1.02
1.11
1.21
1.00
Basic Shares Outstanding
85,220.50
94,276.20
105,571.00
164,437.50
225,439.10
EPS (Diluted)
0.73
1.02
1.11
1.21
1.00
Diluted Shares Outstanding
85,220.50
94,276.20
105,571.00
164,437.50
225,439.10
EBITDA
62,255.00
94,158.00
99,659.00
145,053.00
222,034.00
Non-Operating Interest Income
59.00
-
-
-
-

About Synergy Pharmaceuticals

View Profile
Address
420 Lexington Avenue
New York New York 10170
United States
Employees -
Website http://www.synergypharma.com
Updated 09/14/2018
Synergy Pharmaceuticals, Inc. engages on the development and commercialization of novel gastrointestinal therapies. Its commercial product, plecanatide, is marketed under the trademark name TRULANCE, which seeks to treat adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. The company was founded by Kunwar Shailubhai on November 15, 2005 and is headquartered in New York, NY.

StatInvestor

Privacy Policy
Feedback

© 2025 StatInvestor All Rights Reserved.